Effect of Corticosteroid Injections on Blood Glucose

Corticosteroid Injections Administered Under Ultrasound Guidance to Diabetic Patients and the Effect on Blood Glucose

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05048264

Acronym

CSI

Enrollment

Registered

2021-09-17

Start date

2023-05-04

Completion date

2024-09-16

Last updated

2025-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesive Capsulitis, Diabetes Mellitus, Hip Osteoarthritis, Knee Osteoarthritis, Shoulder Osteoarthritis, Steroid Diabetes

Keywords

Diabetes, Corticosteroids, Injection, Shoulder, Pain, Osteoarthritis, Knee, Hip

Brief summary

The purpose of this study is to measure the effect of various corticosteroids administered to the shoulder, knee and hip joints in diabetic patients on resultant blood glucose readings.

Detailed description

The purpose of this study is to measure the effect of various corticosteroids administered to the shoulder, knee, and hip joints in diabetic patients on resultant blood glucose readings. Corticosteroid injections (CSI) are frequently used in orthopedic settings in order to treat a wide array of orthopedic issues, including osteoarthritis, bursitis, tendinitis, and many others. The effect of diabetes on the musculoskeletal system and its role in orthopedic disease has been well-documented. Current evidence demonstrates that corticosteroids, even when administered through a local musculoskeletal injection, can lead to temporary increases in blood glucose. Ultrasound guidance was not explicitly used in any of the studies examining the impact of steroids on blood glucose. The utilization of ultrasound guidance has been shown to increase accuracy when performing injections into the subacromial space as well as the glenohumeral joint when compared to palpation/landmark-guided injections.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Known diabetic patients ages 40-75 undergoing clinically indicated standard of care corticosteroid shoulder, knee and hip joint injection * Ability to perform daily blood glucose testing * Can receive and send text messages

Exclusion criteria

* Previous joint arthroplasty * Corticosteroid injection at other sites in the body within the past month * Systemic corticosteroid within the last month other than asthma inhaler * Anyone who are unable to read and/or understand English * Pregnant women (self-report)

Design outcomes

Primary

Measure	Time frame	Description
Change in blood glucose measures	Baseline & 2 weeks	Reported daily glucose measures from baseline to two week after injection

Countries

United States

Outcome results